To analyse the mechanisms underlying<br>immediate and non-immediate HRs to COVID-19 vaccines, to evaluate the role of in vivo and in vitro tests in diagnosis to these HRs, to define the best management to patient confirmed as allergic or with atopic backgroung and to develop a guideline which can help the physicians by providing an accurate approach.

IG Drug Allergy

Chair: Annick Barbaud
Secretary: Maria Torres